Fedratinib Administration via Nutritional Supplements

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Patients with myelofibrosis who have difficulty taking fedratinib capsules due to gastrointestinal discomfort or inability to take medications orally require alternative administration methods that do not compromise the effectiveness of the treatment.

Innovation Solution

Administering fedratinib in conjunction with a nutritional supplement, either concomitantly or sequentially, in various formulations such as powders, suspensions, or liquids, to reduce gastrointestinal discomfort and improve tolerability, potentially through nasogastric tubes if necessary.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If fedratinib is administered as oral capsules to patients with myelofibrosis, then the treatment effectiveness is maintained, but gastrointestinal discomfort and inability to take medications orally worsen patient compliance

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the physical state and formulation parameters of fedratinib from traditional oral capsules to alternative delivery forms including liquid formulations, transdermal patches, and rectal suppositories. This allows the medication to be administered to patients who cannot take oral medications due to gastrointestinal discomfort, thereby maintaining treatment effectiveness while improving patient compliance

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces alternative administration routes and formulation intermediaries (such as liquid vehicles for non-orally administered formulations, transdermal adhesives, and rectal delivery systems) that serve as mediators between the drug and patients who cannot tolerate oral administration, thus resolving the contradiction between maintaining efficacy and improving compliance

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If fedratinib capsules are administered to patients with severe gastrointestinal symptoms, then the pharmacological effect is achieved, but gastrointestinal discomfort increases

Engineering Contradiction:

Improvepharmacological effectVSAvoidgastrointestinal discomfort

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the active ingredient fedratinib from its traditional oral capsule form and reformulates it into alternative delivery systems that bypass the gastrointestinal tract, such as transdermal patches that deliver the drug through the skin and rectal suppositories that avoid the upper GI tract, thereby maintaining pharmacological effect while reducing gastrointestinal discomfort

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent inverts the traditional administration route by moving from oral administration (which causes GI discomfort) to non-oral routes such as transdermal and rectal administration, thereby achieving the same therapeutic effect while avoiding the harmful gastrointestinal side effects

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS20240358722A1Methods of administering fedratinib

Publication Date: 2024.10.31 IMPACT BIOMEDICINES INC

AI summary

The present disclosure provides methods of administering fedratinib that are useful for patients unable to take pills. In particular the present disclosure provides methods of administering fedratinib with a nutritional supplement.